Scandinavian ChemoTech reaches success in the Animal Care business area
In January, Scandinavian ChemoTech's new product, VetIQure™, for veterinary medicine was evaluated at a Swedish veterinary clinic with promising results.
ChemoTech has since the launch of IQwave™ treated patients on the human side and, after intensive development work, has introduced the company's first product for Dynamic Electroporation on animals.
ChemoTech's new product designed for veterinary medicine has been named VetIQure™ and shares the unique features of IQwave™, which makes the treatment tumour specific and dynamic, to also treat larger tumors and reduce side effects.
The animal that has been treated has had recurrence of cancer after previous surgical and radiation treatment. The first preliminary evaluation after treatment with the VetIQure™ show a clear improvement in the size, area and volume of the tumour.
“It is very gratifying that we get such good indications of the treatment results this early in the first clinical evaluation. The promising result indicates that our technology is working well within veterinary medicine. ChemoTech will continue its work on clinical validation of our patented tumour specific electroporation during the year for veterinary medicine. ", says Anders Johnsson, Business Unit Director for Animal Care.
Svensk översättning:
Scandinavian ChemoTech når framgångar inom affärsområdet Animal Care
Under januari har Scandinavian ChemoTech’s nya produkt, VetIQure™, för veterinärmedicin utvärderats på en svensk veterinär klinik med lovande resultat.
ChemoTech har sedan lanseringen av IQwave™ behandlat patienter på humansidan och har efter intensivt utvecklingsarbete introducerat bolagets första produkt för Dynamisk Elektroporation på djur.
ChemoTechs nya produkt som är avsedd för veterinärmedicin har fått namnet VetIQure™ och delar de unika funktionerna som finns i IQwave™, som gör behandlingen tumörspecifik och dynamisk, för att även kunna behandla större tumörer och minska biverkningar.
Djuret som behandlats har efter tidigare kirurgi- samt strålningsbehandling fått återfall av sin cancer. De första preliminära undersökningarna efter behandling med VetIQure™ visar en klar förbättring vad gäller tumörens storlek, yta och volym.
"Det är oerhört glädjande att vi så här tidigt i den första kliniska utvärderingen får så goda indikationer på bra behandlingsresultat. Det lovande resultatet indikerar att vår teknologi fungerar väl inom veterinärmedicinen. ChemoTech kommer under året fortsätta sitt arbete med klinisk validering av vår patenterade tumörspecifika elektroporation för veterinärmedicin.", säger Anders Johnsson, Business Unit Director för Animal Care.
For further information please contact:
Mohan Frick, Co-Founder and CEO
+46 (0)10-218 93 00
Certified Adviser: Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250, E-mail: ca@vhcorp.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at: www.chemotech.se.